HEPATITIS DRUGS MARKET ANALYSIS

Hepatitis Drugs Market – Insights

Hepatitis B is a viral infection that affects the liver and leads to acute and chronic liver disorder. According to World Health Organization (WHO) 2018, it is estimated that about 780,000 people die each year due to complication of hepatitis B, such as liver cirrhosis and liver cancer. Hepatitis B virus (HBV) is highly contagious, and is transmitted through contact with the blood or other body fluids of an infected person.

The global hepatitis drugs market size was valued at US$ 21,148.3 million in 2019, and is expected to witness a CAGR of 3.2% over the forecast period (2019 – 2027).

Global Hepatitis Drugs Market Share (%) Analysis, By Drug Class, 2019

To learn more about this report, request a free sample copy

Source: Coherent Market Insights Analysis (2019)

Increasing launches of new drugs and regulatory approvals for hepatitis drugs is expected to drive growth of global hepatitis drug market.

Increasing approvals for hepatitis drugs from regulatory authorities is expected to drive the global hepatitis drugs market growth during the forecast period. For instance, in 2016, the U.S. FDA approved the Elbasvir drug for the treatment of hepatitis C, Elbasvir is a highly potent and selective NS5A inhibitor of the hepatitis C virus NS5A replication complex.

Launch of new drugs for hepatitis treatment is expected to drive growth of the hepatitis drugs market during the forecast period. For instance, in 2018, Natco Pharma has launched a fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, in India.

Hepatitis Drugs Market Restraints

The high capital requirement for manufacturing hepatitis drugs is expected to hinder growth of the hepatitis drugs market over the forecast period. Hepatitis drugs are costly as the manufacturing process requires expensive raw materials such as active pharmaceutical ingredients (APIs) and drug intermediates. The production, isolation, and usage of raw materials for pharmaceutical and biopharmaceutical drug production, is a complex process and requires a skilled workforce, which adds to the overall cost of the pharmaceuticals.

Hepatitis Drugs Market- Regional Insights

On the basis of region, the global hepatitis drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global hepatitis drugs market over the forecast period, owing to increasing government initiative for the prevention of HBV infection. For instance, in 2017, the U.S. Department of Health And Human Service started the National Viral Hepatitis Action Plan 2017-2020 (Action Plan) to fight against viral hepatitis in the US. The plan outlines strategies to achieve four major goals between 2017 and 2020, such as preventing new viral hepatitis infections, reducing deaths and improving the health of people with viral hepatitis.

Asia Pacific is expected to witness a rapid growth in the global hepatitis drugs market over the forecast period owing to rising demand for generic drugs in this region. For instance in 2015, Gilead licensed its hepatitis C drug Sovaldi to seven generic drug manufacturers companies in India to make and sell a low-cost version of the medicine in 91 emerging economies.

Global Hepatitis Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

To learn more about this report, request a free sample copy

Source: Coherent Market Insights Analysis (2019)

Key players operating in the global hepatitis drugs market include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.